1.Propranolol use in a psychiatric in-patients unit(I).
Seiongho MIN ; Jinhan PARK ; Jongho SHIN
Journal of Korean Neuropsychiatric Association 1992;31(1):50-59
No abstract available.
Propranolol*
2.Three Cases of Infantile Hemanioma Treated with Topical Timolol.
Neonatal Medicine 2014;21(2):138-143
Infantile hemangioma is a common, benign tumor of infancy. Although systemic propranolol was found to be effective in the treatment of infantile hemangioma, its use is often challenging for clinicians owing to its potential side effects. Recent small studies have suggested that the topical use of timolol maleate gel, a non-selective beta-adrenergic antagonist, might be effective for the treatment of superficial infantile hemangioma. Here, we report three cases of infantile hemangioma of different sizes and depths treated with the topical timolol maleate gel-forming solution.
Hemangioma
;
Propranolol
;
Timolol*
3.Study on preparations of sustained release propranolol tablets
Pharmaceutical Journal 2005;347(3):5-8
Study on the influence of appropriate sustained-release excipients on the release of propranolol hydrochloride from experimental sustained-release tablet. Hydroxyl propyl methyl cellulose and Avicel PH 101 could protect the release of propranolol hydrochloride from sustained-release tablet. Establish the coating with 2 types of polymers HPMC and Eudragit L100. Test the degree of dissolution during 12 hours and compare to the reference tablet. The release of propranolol hydrochloride from sustained release tablet prepared by the formula 20th was similar to that of reference tablet, the coefficient of f2=64.54. At the same time, the quantitative method of serum propranolol was established, in order to assess the in vivo ability of products
Propranolol
;
Delayed-Action Preparations
4.Giant Infantile Hemangioma Treated with Beta-blocker with Intermittent Triamcinolone Intralesional Injection.
Gil HAN ; Jae We CHO ; Kyu Suk LEE
Korean Journal of Dermatology 2015;53(8):658-659
No abstract available.
Hemangioma*
;
Injections, Intralesional*
;
Propranolol
;
Triamcinolone*
5.Successful and safe treatment of hemangioma with oral propranolol in a single institution.
Sun Hee CHUNG ; Dong Hyuk PARK ; Hye Lim JUNG ; Jae Won SHIM ; Deok Soo KIM ; Jung Yeon SHIM ; Moon Soo PARK ; Hong Hoe KOO
Korean Journal of Pediatrics 2012;55(5):164-170
PURPOSE: Dramatic improvement of hemangioma to propranolol has been recently reported; however, details on dose and duration of treatment, potential risks, and monitoring have not been determined. The objective of this study is to describe and analyze the use of propranolol as a first-line treatment or as a single therapy in management of complicated hemangioma. METHODS: A retrospective chart review of eight patients diagnosed with hemangioma and treated with propranolol in Kangbuk Samsung Hospital from February 2010 to April 2011 was performed. RESULTS: Eight patients with hemangioma with functional impairment, cosmetic disfigurement, or rapid growth were treated with propranolol. Five patients had solitary facial hemangioma. The mean age of symptoms at onset was 5 weeks. The median age for starting propranolol treatment was 5.5 months. Propranolol at 2 mg/kg/day was finally administered in divided doses with a gradual increase. Significant regression was observed in seven patients, and shrinkage in size, softening in consistency, and decrease in redness were evident within 4 weeks. Among them, six patients were still taking propranolol, and one patient had stopped after 12 months. Other one patient did not show significant improvement with satisfactory result after 3 months of propranolol use. Treatment with propranolol was well tolerated and had few side effects. No rebound growth was observed in any of the patients. CONCLUSION: We observed that use of propranolol was very effective in treatment of hemangioma without obvious adverse effects or relapse.
Cosmetics
;
Hemangioma
;
Humans
;
Propranolol
;
Recurrence
;
Retrospective Studies
6.The Effects of Propranolol and MJ 1999 against Ventricular Fibrillation during Piofound Hypothermia in Dogs .
Korean Journal of Anesthesiology 1974;7(1):19-33
Profound hypothermia (15 degrees C) was induced in 36 mogrel dogs anesthetized with nitrous oxide-oxygen-d-tubocurarine. Prcpranolol (0.3 mg/kg) or MJ 1999(0.8 mg/kg) was administered intravenously 10 minutes prior to the start of cooling. Significant protection against ventricular fibrillation was provided by MJ 1999, but not by propranolol. With available evidence that hypothermia causes increased catecholamine release and that MJ 1999 is more specific in its beta-adrenergic blocking prcperties than propranolol, the authors findings suggest that ventricular fibrillation during hypothermia is due to beta-adrenergic hyperactivity.
Animals
;
Dogs*
;
Hypothermia*
;
Propranolol*
;
Sotalol*
;
Ventricular Fibrillation*
7.The Effects of Succinylcholine on Cardiac Rates after Pretreatment with Propranolol and Lidocaine .
Korean Journal of Anesthesiology 1978;11(4):335-339
During ether anesthesia in man, succinylcholine(lmg/kg of body weight) was administered intravenously after pretreatment with 0.2% lidocaine 50-60mg or Inderal(1. 0mg). The effects were as follows: 1) Heart rates were increased during ether anestheaia. 2) Lidocaine produced no effects on heart rates rncreased by ether, but heart rates were decreased following administration of succinylcholine. 3) Inderal decreased heart rates, increased by ether anesthesia. Heart rates were increased following administration of succinylcholine.
Anesthesia
;
Ether
;
Heart Rate
;
Lidocaine*
;
Propranolol*
;
Succinylcholine*
8.Effect of Propranolol on Serum K+ Changes Induced by Succinylcholine .
Seong Shick SHIN ; Kyung Yeon YOO ; Chang Young CHUNG ; Woong Mo IM
Korean Journal of Anesthesiology 1988;21(1):60-66
Succinylcholine induces a small increase in serum K+ (0.3~0.5mEq/l) in normal patients, but it may produce fatal increases in sensitive conditions, including severe burn, massive trauma, tetanus and neuromuscular disorders. Recently, interest has been focussed on the role of the adrenergic system in extrarenal potassium hemeostasis. According to this concept, beta-adrenergic stimulation enhances and conversely a blockade imparis celluar uptake of potassium. Meanwhile propranolol, a beta-adrenergic blocker, is an incresingly, common drug among surgical patients. Therefore, the present experiment was carried out on 66 patients in order to determine whether propranolol augments or prolongs the increases in serum K+ following succinylcholine injection(2mg/kg, I.V.). Serum K+ and Na+ levels were measured just prior to induction and at 3,5,10,30,60,90 minutes following succinylcholine administration. The patients were divided into three groups: Group 1: 26 patients without propranolol treatment, Group 2: 20 patients pretreat with divided doses of propranolol (320 mg b.i.d. p.o.). and Group 3: 20 patients on chronic propranolol therapy. The results were as follows. 1) Baseline K+ valuses were significantly higher in propranolol treated patients(Groups 2 and 3) than in non-treated patients(Group 1). 2) The magnitude of maximum increases in serum K+ following succinylcholine was 0.19mEq/l, 0.16mEq/l and 0.21mEq/l in group 1,2 and 3, respectively. 3) The time to peak increases in K+ was 30min, 5min and 3 min following succinylcholine in group 1,2 and 3, respectively. 4) Serum Na+ decreased significantly following succinylcholine administration in all groups, but there was no significant difference among the groups at other times. These results indicate that propranolol neither augments nor prolongs increases in serum K+ following succinylcholin injection. Thus succinylcholine can be used safely in the presence of a beta-adrenergic blockade.
Burns
;
Humans
;
Potassium
;
Propranolol*
;
Succinylcholine*
;
Tetanus
9.Effect of beta-adrenergics on the Survival and Production of Nitric Oxide in the Cultured Trabecular Meshwork Cells.
Young Hwan JEON ; Sung Hoon KIM ; Jae Woo KIM
Journal of the Korean Ophthalmological Society 2003;44(12):2905-2910
PURPOSE: To investigate the effect of beta-adrenergics on the production of nitric oxide (NO) in cultured trabecular meshwork cells. METHODS: Primarily cultured porcine trabecular meshwork cells were exposed to timolol and to propranolol at various concentrations. Cellular survival was assessed by MTT assay and the production of nitrite was assessed by Griess reaction after 24 hours and 3 days respectively. Also investigated was the effect of co-administraton of timolol and isoproterenol. RESULTS: After exposure for 24 hours, neither drug affected the cellular survival. Timolol and propranolol inhibited the production of NO significantly (p<0.05). Isoproterenol abolished timolol-induced inhibition of NO production after 24 hours. These results were similar after exposure for 3 days. CONCLUSIONS: Both timolol and propranolol inhibit the production of NO in trabecular meshwork cells and isoproterenol abolished this effect. These results suggest that beta-adrenerics involves in the production of NO in trabecular meshwork cells.
Isoproterenol
;
Nitric Oxide*
;
Propranolol
;
Timolol
;
Trabecular Meshwork*
10.Effects of Dihydrochlorothiazide, Propranolol, and Prazosin on Serum Lipids in Patients with Essential Hypertension.
Seung Bum JIN ; Young Woo RHEE ; Seok Won CHANG ; Ki Cheol KIM ; Soek Pil KIM ; Chang Sup SONG
Korean Circulation Journal 1985;15(2):329-336
Three groups of patients with newely diagnosed hypertension, or with hypertension not optimally controlled by previous treatment, completed a comparative study on the effects of Dihydrochlorothiazide, propranolol, and prazosin on plasma lipids after three months therapy. The drugs showed equipotent antihypertensive effects(P<0.01). Dihydrochlorothiazide administration was associated with a significant elevation of total cholesterol(42%, P<0.05), and triglyceride(8.1%, P<0.01). Changes of HDL-C(5.1%), LDL-C(3.3%), and cholesterol ratio(-4.8%) were not significant. Propranolol administration was associated with significant elevation of total cholesterol(3.8%, P<0.05), triglyceride(14.5%, P<0.005), and LDL-C(5.6%, P<0.005). Reduction of HDL-C(-7.8%, P<0.05) and cholesterol ratio(-14.7%, p<0.005) was also statistically significant. Prazosin administration was associated with significant decrease in total cholesterol(-6.6%, P<0.005), triglycride(-9.6%, P<0.005), and LDL-C(-11.7%, P<0.005), and significant elevation of HDL-C(10.6%,P<0.005) and cholesterol ratio(24.2%, P<0.005) was noted.
Cholesterol
;
Humans
;
Hydrochlorothiazide*
;
Hypertension*
;
Plasma
;
Prazosin*
;
Propranolol*